At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVCR NovoCure
Post-Market Trading 11-22 19:12:13 EST
17.73
+0.64
+3.74%
盘后17.31
-0.42-2.37%
17:11 EST
High17.89
Low17.10
Vol657.82K
Open17.20
D1 Closing17.09
Amplitude4.65%
Mkt Cap1.92B
Tradable Cap1.75B
Total Shares108.20M
T/O11.55M
T/O Rate0.67%
Tradable Shares98.52M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Novocure Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.